Mertens W C, Bramwell V H
Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Harper Hospital, Detroit, MI 48201, USA.
Curr Opin Oncol. 1996 Jul;8(4):299-304. doi: 10.1097/00001622-199607000-00006.
Steady progress in the delineation of prognostic factors and the identification of genetic alterations and of potential mechanisms of oncogenesis mark the contributions to the literature on osteosarcoma for the past year. A new cytokine and chemotherapy combination has shown promise, and additional work on chemotherapy regimens containing ifosfamide will undoubtedly stimulate interest in a new generation of randomized clinical trials that will be essential for further refinement of therapy for osteosarcoma.
过去一年里，在骨肉瘤预后因素的界定、基因改变的识别以及肿瘤发生潜在机制的研究方面均取得了稳步进展，这些成果为骨肉瘤相关文献增添了内容。一种新的细胞因子与化疗联合方案已显示出前景，而针对含异环磷酰胺化疗方案的更多研究无疑将激发人们对新一代随机临床试验的兴趣，这些试验对于进一步优化骨肉瘤治疗至关重要。
